Best Medical Stocks To Invest In 2017


This Top Pick for 2017 may very well have the best and broadest early-stage oncology pipeline with 12 drug development candidates, suggests Jay Silverman, editor The Medical Technology Stock Letter.

Incyte (INCY) is poised for a strong performance in 2017 that will be driven by three major catalysts.

The first is that the firm’s drug Jakafi will continue to be a compelling and sustainable high margin long-term growth driver for myeloproliferative disorders myelofibrosis (MF) and polycythemia vera (PV). 


The recent failure from a competitor’s Phase III studies of momelotinib has removed a major uncertainty on the revenue front for INCY’s key commercial product.  The potential upside of Jakafi sales in both MF and PV represents a significant growth opportunity. 

Partner Eli Lilly (LLY) will sell INCY’s baricitinib in rheumatoid arthritis and we expect a strong commercial launch that will be driven by the potential to be another “Best in Class” drug. 

Best Medical Stocks To Invest In 2017: Union Pacific Corporation(UNP)


Advisors’ Opinion:

  • [By Ben Levisohn]

    A strange turn of events has sent shares of CSX (CSX)–and other railroads, including Union Pacific (UNP) and Canadian Pacific Railway (CP)–soaring today. It all started when Hunter Harrison announced that he would leave Canadian Pacific ahead of schedule to team up with activist investor for the turnaround of another railway company. That company is thought to be CSX.

Best Medical Stocks To Invest In 2017: Ethan Allen Interiors Inc.(ETH)


Advisors’ Opinion:

  • [By Dan Caplinger]

    Wednesday was a strong day for the stock market, as the Dow finished up nearly 100 points and the S&P 500 and Nasdaq both posted gains as well. Investors remained generally upbeat about the prospects for the U.S. economy in 2017, and a rise in crude oil prices helped lift the energy sector higher during the market session. Yet comments during a press conference from President-elect Donald Trump weighed on the healthcare sector, and some individual stocks took particularly hard hits. Among the worst performers were Perrigo (NYSE:PRGO), Novadaq Technologies (NASDAQ:NVDQ), and Ethan Allen Interiors (NYSE:ETH). Below, we’ll look more closely at these stocks to tell you why they did so poorly.

Best Medical Stocks To Invest In 2017: CSX Corporation(CSX)


Advisors’ Opinion:

  • [By Ben Levisohn]

    CSX (CSX) soared to the top of the S&P 500 today after railroad operator was upgraded by BMO Capital Markets following its big activist-inspired move last week.

    Agence France-Presse/Getty Images

    CSXgained 3.7% to $45.99 today, while the S&P 500 declined 0.3% to 2,265.20.

    BMO’sFadiChamoun andTarunJoshi explain why they upgraded CSX to Outperform from Market Perform:

    We are upgrading CSX shares to Outperform from Market Perform and raising our target price to $55 from $38. We see upside to around $80 over the medium term. Our constructive thesis is predicated on Mantle Ridge LP being successful in its effort to install Hunter Harrison as CEO of CSX. We believe that the probability of this occurring is fairly high without going down the road of a bruising proxy battle.


    CSX’s market capitalization rose to $43.1 billion today from $41.4 billion yesterday. It reported net income of $2 billion on sales of $11.1 billion in 2016.

  • [By Dan Caplinger]

    The railroad business has been tough lately, and companies like CSX (NASDAQ:CSX) have had to deal with the ups and downs of the industrial economy and its impact on shipping volume. Coming into Wednesday’s first-quarter financial report, however, CSX investors were excited about the prospects for a resurgence in the railroad’s growth prospects.

  • [By Ben Levisohn]

    A strange turn of events has sent shares of CSX (CSX)–and other railroads, including Union Pacific (UNP) and Canadian Pacific Railway (CP)–soaring today. It all started when Hunter Harrison announced that he would leave Canadian Pacific ahead of schedule to team up with activist investor for the turnaround of another railway company. That company is thought to be CSX.

    Getty Images

    That activist interest, more than anything CSX revealed in its earnings report on Tuesday, was enough to get Morgan Stanley’sRavi Shanker and team to upgrade its share to Equal Weight from Underweight. They explain:

    The blue-sky potential is likely to continue with the news today that Mr. E. Hunter Harrison will retire from Canadian Pacific and with the WSJ reporting that he is close to teaming up with an activist investor to target CSX…In the near term, given the potential activist interest, the stock is not likely to trade on fundamentals until a resolution, which drives our upgrade from UW to EW. Our PT goes from $24 to $37 or ~18x our FY18e EPS above the peer group but close to the mid-point of the $56 bull scenario and $24 bear scenario amongst the outcomes outlined above.

    Shares of CSX have jumped 18% to$43.55 at 11:35 a.m. today, whileCanadian Pacific Railway has climbed 4% to $151.01, and Union Pacific, which released better-than-expected earnings today, has gained 2.4% to $106.21.

Leave a Reply

Your email address will not be published. Required fields are marked *